Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Railet Rodriguez

Nurse Practitioner, Primary Care Altamonte Springs, FL Nurse Practitioner

NPI 1104374164 CMS profile 10414583

829 Douglas Ave, Altamonte Springs, FL 32714

Open in the dashboard

General payments

$14,082

592 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Railet Rodriguez of Altamonte Springs, FL is reported in the CMS Open Payments database as having received $14,082 across 592 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,760 248
2024 General $4,555 195
2023 General $3,567 136
2022 General $160 10
2021 General $40 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Railet Rodriguez
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Railet Rodriguez were reported at $5,760. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Railet Rodriguez Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $40 $137 $39–$445 $132
2022 $160 $139 $44–$421 $149
2023 $3,567 $163 $53–$481 $160
2024 $4,555 $176 $54–$511 $164
2025 $5,760 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,122 92 payments
  2. Teva Pharmaceuticals USA, Inc. $1,066 40 payments
  3. Neurocrine Biosciences, Inc. $999 40 payments
  4. ACADIA Pharmaceuticals Inc $850 42 payments
  5. UCB, Inc. $746 24 payments
  6. Eisai Inc. $663 28 payments
  7. Pfizer Inc. $631 51 payments
  8. Amneal Pharmaceuticals LLC $617 24 payments
  9. Alexion Pharmaceuticals, Inc. $530 15 payments
  10. Lilly USA, LLC $523 23 payments
  11. Other $5,335 213 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,064 591 payments
  2. Education $18 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $1,473 60 payments
  2. QULIPTA $1,240 56 payments
  3. Austedo XR $1,036 39 payments
  4. INGREZZA $999 40 payments
  5. Leqembi $846 35 payments
  6. NUPLAZID $829 41 payments
  7. ZAVZPRET $631 51 payments
  8. NURTEC ODT $584 47 payments
  9. ULTOMIRIS $530 15 payments
  10. CREXONT $492 16 payments
  11. Other $7,237 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

274

Median for Nurse Practitioner: 389

Drug cost

$8,967

Median for Nurse Practitioner: $21,885

Branded share of claims

7.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Piroxicam Generic 17 $5,372
Pregabalin Generic 87 $1,897
Clonazepam Generic 59 $596
Carbidopa-Levodopa Carbidopa/Levodopa Brand 20 $581
Tramadol Hcl Generic 34 $290
Zolpidem Tartrate Generic 21 $149
Diazepam Generic 14 $46
Temazepam Generic 11 $23
Alprazolam Generic 11 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
  • ACADIA Pharmaceuticals Inc $492
$492 — —
UBRELVY
  • AbbVie, Inc. $335
$335 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $306
$306 — —
Leqembi
  • Eisai Inc. $251
  • Biogen, Inc. $24
$275 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $250
$250 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

592 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record